PLoS ONE · 2019 · 54 citations · 42 references
MedicineOrthopaedic SurgeryOrthopedic SurgeryCartilage RepairCell TherapyOrthopedicsCartilage DegenerationCartilage RegenerationIntra-articular TherapyJoint DiseaseMesenchymal Stem Cell TherapyOsteoarthritisCartilage TransplantationIntra-articular AdministrationIntra-articular Cell AdministrationLameness TreatmentRegenerative Injection TherapiesStem Cell-based Cartilage RegenerationUmbilical Cord-derived CellsUmbilical Cord-derived Mesenchymal Stromal Cells
The purpose of this prospective study was to evaluate the effects of single and repeated intra-articular administration of allogeneic, umbilical cord-derived, neonatal mesenchymal stem cells (MSC) in horses with lameness due to osteoarthritis (OA) of a metacarpophalangeal joint (MPJ). Twenty-eight horses were included. Horses were divided into two groups. Horses in group MSC1 received an MSC injection at M0 and a placebo injection at M1 (1 month after M0). Horses in group MSC2 received MSC injections at M0 and at M1. Joint injections were performed with a blinded syringe. Clinical assessment was performed by the treating veterinarian at M1, M2 and M6 (2 and 6 months after M0), including lameness evaluation, palpation and flexion of the joint. Radiographic examination of the treated joints was performed at inclusion and repeated at M6. Radiographs were anonymized and assessed by 2 ECVDI LA associate members. Short term safety assessment was performed by owner survey. A 2-month rehabilitation program was recommended to veterinarians. There was a significant improvement of the total clinical score for horses in both groups. There was no significant difference in the total clinical score between groups MSC1 and MSC2 at any time point in the study. There was no significant difference in the total radiographic OA score, osteophyte score, joint space width score and subchondral bone score between inclusion and M6. Owner-detected adverse effects to MSC injection were recorded in 18% of the horses. Lameness caused by OA improved significantly over the 6-month duration of the study after treatment with allogeneic neonatal umbilical cord-derived MSCs combined with 8 weeks rest and rehabilitation. There is no apparent clinical benefit of repeated intra-articular administration of MSCs at a 1-month interval in horses with MPJ OA when compared to the effect of a single injection.
42
Stem cell therapy in a caprine model of osteoarthritis
Mary Murphy, David J. Fink, Ernst B. Hunziker et al. · Arthritis & Rheumatism · 2003 · 1.1K citations
S. Jyothi Prasanna, D Gopalakrishnan, Shilpa Rani Shankar et al. · PLoS ONE · 2010 · 483 citations · Full text
José Matas, Mario Orrego, Diego Amenábar et al. · Stem Cells Translational Medicine · 2018 · 415 citations · Full text
Ebughe Godwin, N. J. Young, Jayesh Dudhia et al. · Equine Veterinary Journal · 2011 · 409 citations · Full text